Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of GB-0669 in healthy volunteers
NCT07050511Phase 1Completed
- Sponsor
- Generate Biomedicines
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing GB-0669 with Placebo (2 arms). Primary endpoint: Safety and tolerability of a single ascending dose of GB-0669. Started Jul 2023; status: completed.
02
Drugs
GB-0669
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07050511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050511.